The Trump administration in its drug pricing “blueprint”
included plans to explore moving certain Medicare Part B drugs into Part D in an
effort to contain rising drug costs (RMA 5/17/18, p. 1). Meanwhile, a new
report from the HHS Office of the Inspector General found that federal
reimbursement for Part D brand-name drugs rose 77% between 2011 and 2015, while
unit costs for these agents jumped 29% on average — nearly six times greater
than the 5% increase in the consumer price index.
SOURCE: HHS Office of
Inspector General analysis of Medicare Part D data, 2011 to 2015. Visit https://oig.hhs.gov/oei/reports/oei-03-15-00080.pdf.
No comments:
Post a Comment